Skip to main content

Table 4 Assessment of circulating angiogenesis modulating proteins as therapy activity predictors

From: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

  

Treatment failure

Objective response or TTF > 4monts

Healthy controls

FGF2 (pg/ml)

N

5

7

8

 

median

3.4

1.8

0.8

 

range

(1.9-23.7)

(0.4-14.8)

(0.2-2.3)

 

p-value

  

0.02*

IL8 (pg/ml)

N

5

7

8

 

median

27.2

5.8

5.8

 

range

(12.2-61.9)

(2.8-18.9)

(1.1-7.5)

 

p-value

  

0.006**

TSP-1 (ng/ml)

N

5

7

8

 

median

125.1

69.6

67.3

 

range

(85.1-328.4)

(24-452)

(9-710.1)

 

p-value

  

0.047

VEGF (pg/ml)

N

5

7

10

 

median

1552

428,6

2094

 

range

(804.3-2785)

(252.4-3116)

(1122-2387)

 

p-value

  

0.074

VEGFR-2 (pg/ml)

N

5

7

8

 

median

13680

13275

12328

 

range

(8945-16465)

(7455-18065)

(8235-17615)

 

p-value

  

0.657